Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) and Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Profitability
This table compares Sol-Gel Technologies and Iterum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
| Iterum Therapeutics | N/A | N/A | -65.54% |
Analyst Ratings
This is a summary of current ratings and target prices for Sol-Gel Technologies and Iterum Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
| Iterum Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Sol-Gel Technologies presently has a consensus price target of $197.50, indicating a potential upside of 184.38%. Given Sol-Gel Technologies’ stronger consensus rating and higher probable upside, research analysts plainly believe Sol-Gel Technologies is more favorable than Iterum Therapeutics.
Institutional & Insider Ownership
26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Sol-Gel Technologies and Iterum Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sol-Gel Technologies | $1.79 million | 126.67 | -$6.13 million | ($5.64) | -12.31 |
| Iterum Therapeutics | $390,000.00 | 4.10 | -$24.77 million | ($0.75) | -0.04 |
Sol-Gel Technologies has higher revenue and earnings than Iterum Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Sol-Gel Technologies has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500.
Summary
Sol-Gel Technologies beats Iterum Therapeutics on 10 of the 15 factors compared between the two stocks.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
